Loading the section
Prices delayed by 15 minutes
Next earnings report: 27 October 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Incyte Corporation trades on Nasdaq under the ticker INCY. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks INCY has traded between 82.82 $ and 132.60 $. As of 09 October 2026 the price stood 60.12 % of the way from the 52-week low to the high.
Over one year INCY shares rose 29.34 %; over six months they rose 16.29 %. Volatility over 90 days is 35.76 %. Dividends are not included: this is price change only, as of 09 October 2026.
INCY trades at a price-to-earnings ratio of 15.7, below the sector median of 24.8. Price to sales is 4.2, above the sector median of 3.9. Price to book is 4.0, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 112.89 | 113.75 | 110.08 | 112.75 | 2M |
| 07 October 2026 | 112.82 | 115.49 | 112.46 | 113.44 | 1M |
| 06 October 2026 | 114.13 | 114.97 | 111.67 | 112.73 | 2M |
| 05 October 2026 | 115.15 | 115.67 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Incyte was built around a single drug for a bone marrow disease and is looking for what will replace it.
The main drug suppresses the signalling pathway that makes bone marrow produce cells incorrectly. It remains the standard of care and supplies the overwhelming share of revenue. That dependence is both a strength and a vulnerability: patent protection has an end date, and the cliff is visible in the calendar well in advance.
A replacement is sought in two directions: a cream for vitiligo and eczema working through the same mechanism, and drugs against particular tumour types. The company is profitable, which is rare for a biotech, and reinvests that profit into development. Risks: the patent term, trial outcomes and insurers' decisions on covering an expensive cream. The company pays no dividend.
Address:1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803, US
Incyte Corporation reported revenue of 5.4B $ and net income of 1.4B $ over the last four quarters. Net margin is 26.71 %. Revenue changed by +21.48 % year over year. Earnings per share are 7.08 $. Market capitalisation is 22.5B $.
INCY has a return on equity of 25.46 %, above the sector median of −41.68 %. Return on assets is 19.51 %, above the sector median of −32.11 %. Operating margin is 30.05 %, above the sector median of −26.84 %.
| 146M |
| BIAFbioAffinity Technologies, Inc. | 4.69 | −16.84 % | 67M |
| ABSIAbsci Corporation | 10.14 | +13.37 % | 39M |
| OABIOmniAb, Inc. | 4.79 | +2.79 % | 7M |
| NRCNRC Health | 20.33 | −0.44 % | 3M |
| 112.83 |
| 114.13 |
| 2M |
| 02 October 2026 | 116.76 | 117.19 | 114.57 | 115.30 | 2M |
| 01 October 2026 | 120.47 | 121.22 | 117.00 | 117.14 | 2M |
| 30 September 2026 | 123.00 | 124.23 | 121.03 | 121.35 | 2M |
| 29 September 2026 | 123.67 | 125.47 | 121.89 | 123.20 | 2M |
| 28 September 2026 | 123.32 | 126.14 | 122.53 | 124.82 | 1M |
| 25 September 2026 | 125.72 | 126.00 | 123.07 | 123.89 | 1M |
| 24 September 2026 | 124.79 | 125.55 | 123.03 | 124.44 | 1M |
| 23 September 2026 | 127.51 | 128.21 | 123.89 | 124.64 | 2M |
| 22 September 2026 | 124.72 | 127.75 | 124.01 | 126.93 | 2M |
| 21 September 2026 | 125.00 | 127.41 | 124.19 | 124.65 | 1M |
| 18 September 2026 | 127.85 | 128.72 | 125.23 | 125.31 | 4M |
| 17 September 2026 | 125.74 | 127.74 | 125.10 | 127.62 | 1M |
| 16 September 2026 | 121.48 | 124.96 | 121.48 | 124.75 | 1M |
| 15 September 2026 | 121.58 | 122.19 | 119.97 | 121.74 | 2M |
| 14 September 2026 | 122.48 | 123.35 | 121.28 | 122.19 | 1M |
| 11 September 2026 | 124.35 | 124.35 | 121.42 | 121.47 | 1M |